{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000061","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-08-12T20:15:35+00:00","discovered_at":"2026-08-12T20:17:00.192560+00:00","generated_at":"2026-08-12T20:17:31.014482+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AEON Biopharma reports Q2 2026 cash $3.4M, completes $15.3M offering, FDA Type 2b expected","bullets":["Q2 2026 cash and equivalents $3.4M as of June 30, 2026; excludes ~$13.6M net proceeds from July public offering.","Completed $15.3M underwritten offering in July 2026; milestone warrants could add $34.0M gross; cash runway into Q1 2027.","FDA BPD Type 2a meeting in Q1 2026 supported ABP-450 analytical approach; Type 2b feedback expected H2 2026.","Regained NYSE American compliance on Aug 3, 2026.","Presented comparability data at AAN (April) and AHS (June) meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000061","json":"https://secwatch.observer/filing/0001837607-26-000061.json","markdown":"https://secwatch.observer/filing/0001837607-26-000061.md","text":"https://secwatch.observer/filing/0001837607-26-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/0001837607-26-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000061/aeon-20260812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:17:31.014482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}